Abcam, ab259021, Human OSTC knockout HEK-293T cell lysate

Size: 1Kit
OSTC KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 7 bp deletion in exon 1.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 7 bp deletion in exon 1.

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-OSTC, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
OSTC also known as oligosaccharyltransferase complex subunit is a component in the N-linked glycosylation pathway. It has a molecular mass of approximately 16 kDa. OSTC is located primarily in the endoplasmic reticulum and displays a ubiquitous expression indicating its presence in various cell types and tissues. This protein is an important player in the assembly and function of the oligosaccharyltransferase complex which catalyzes the transfer of oligosaccharides onto nascent peptides a process important for proper protein folding and stability.
Biological function summary
The oligosaccharyltransferase complex including OSTC plays a significant role in protein modification. The complex facilitates the attachment of glycans to asparagine residues on target proteins an essential post-translational modification process. Being a part of this multi-protein complex OSTC contributes actively to maintaining cellular homeostasis by influencing protein quality control and secretion.
Pathways
OSTC's involvement is embedded in the N-glycosylation pathway which is important for the proper folding and function of numerous glycoproteins. This pathway intersects with the protein processing pathway in the endoplasmic reticulum where OSTC collaborates with other protein components like OST48 and ribophorin ensuring efficient protein maturation. These interactions highlight OSTC's role in maintaining cellular function through its integration into key biochemical pathways.
Several studies link OSTC to congenital disorders of glycosylation which arise from dysfunctional glycosylation processes. Abnormal OSTC expression or function may result in disrupted protein folding and stability contributing to neurodevelopmental disorders and immunodeficiencies. Furthermore OSTC's interaction with proteins involved in the glycosylation pathway can accentuate phenotypic manifestations in ER stress-related diseases highlighting the importance of this target in clinical research and therapy development.